Brokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Target Price at $422.27

Key Points

• Medpace Holdings, Inc. has received a consensus rating of "Reduce" from 16 research firms, with three analysts recommending a sell, eleven a hold, and two a buy.
• The average 1-year price target for Medpace is reported to be $422.27, despite recent price target adjustments by various analysts upwards to $490.00.
• Medpace's recent quarterly earnings showed a profit of $3.10 EPS, exceeding expectations, alongside a 14.2% revenue increase year-over-year.

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have been assigned a consensus rating of "Reduce" from the sixteen ratings firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $422.2727.

A number of analysts have recently commented on MEDP shares. Truist Financial boosted their target price on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Robert W. Baird lifted their price objective on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Barclays raised their price target on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Finally, Rothschild & Co Redburn cut shares of Medpace from a "buy" rating to a "neutral" rating and raised their price target for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the general counsel owned 10,343 shares of the company's stock, valued at $4,654,350. This trade represents a 22.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total value of $4,800,000.00. Following the completion of the transaction, the vice president owned 57,500 shares in the company, valued at approximately $27,600,000. This represents a 14.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock worth $74,111,427 in the last three months. Company insiders own 20.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its position in shares of Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after buying an additional 102,015 shares during the last quarter. Wasatch Advisors LP raised its holdings in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after buying an additional 116,354 shares during the period. Mawer Investment Management Ltd. increased its holdings in Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company's stock worth $256,559,000 after purchasing an additional 121,213 shares during the period. AQR Capital Management LLC boosted its position in shares of Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company's stock worth $193,269,000 after purchasing an additional 81,637 shares in the last quarter. Finally, Bessemer Group Inc. lifted its holdings in shares of Medpace by 1.1% in the 1st quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock valued at $177,411,000 after buying an additional 6,225 shares during the period. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

MEDP stock traded down $0.74 during mid-day trading on Friday, hitting $497.86. 17,286 shares of the stock were exchanged, compared to its average volume of 438,838. Medpace has a 12 month low of $250.05 and a 12 month high of $506.55. The stock has a market capitalization of $13.99 billion, a price-to-earnings ratio of 37.02, a PEG ratio of 3.14 and a beta of 1.44. The business has a fifty day moving average price of $446.89 and a 200 day moving average price of $355.45.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company's revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities analysts forecast that Medpace will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.